Clinicopatholgic Characteristics to the Relapse on Ductal Carcinoma In Situ: Ki-67 Index as the Most Influential Prognostic Factor

다국어 초록 (Multilingual Abstract)

Purpose: The biggest concern related to ductal carcinoma in situ (DCIS) is local recurrence and recurrence patterns. The purpose of this study was to investigate the relationship between clinicopathological factors and relapse in patients treated with DCIS.
Methods: We reviewed medical records of 104 patients who were diagnosed as DCIS between January 1999 and December 2015 at a single institute. We compared and analyzed clinicopathological factors such as age at diagnosis, preoperative lesions on ultrasonography, preoperative tumor markers, operation methods in the breast, histological grade, nuclear grade, resection margin, comedonecrosis, estrogen receptor/progesterone receptor expression, human epidermal factor receptor 2/neu expression, Ki-67, postoperative implementation of adjuvant hormonal therapy, and radiotherapy by dividing them into recurrent and non-recurrent groups.
Results: Seventeen patients (16.3%) of 104 patients relapsed in the ipsilateral or contralateral breast. The median follow-up period of non-relapsed group was 4.9 years (range, 0.5–19.15) and the median follow-up period of relapsed group was 3.5 years (range, 1.4–14.13). Clinicopathological factors that were significantly related to relapse were nuclear grade (p=0.022) and Ki-67 (p=0.025) based on the results of chi-square or Fisher’s exact analysis. In multivariate analysis using logistic regression, Ki-67 (p=0.021) was significantly associated with DCIS relapse.
Conclusion: This study suggested that the higher Ki-67 over 14% was strongly associated with DCIS relapse.

참고문헌 (Reference)

1 이은혜 ; 박보영 ; 김남순 ; 서현주 ; 고경란 ; 민준원 ; 신명희 ; 이기헌 ; 이시연 ; 최나미 ; 허민희 ; 김동일 ; 김민정 ; 김성용 ; 선우성 ; 당지연 ; 김수영 ; 김열 ; 이원철 ; 정준, "유방암 검진 권고안 개정안" 대한의사협회 58 (58): 408-419, 2015

2 Lin CY, "Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions" 31 : 562-568, 2018

3 Di Cesare P, "The relationships between HER2 overexpression and DCIS characteristics" 23 : 307-314, 2017

4 Bayard S, "Screening mammography mitigates breast cancer disparities through early detection of triple negative breast cancer" 80 : 430-437, 2021

5 김정연 ; 박경미 ; 강구현 ; 김현정 ; 곽금희 ; 신영주, "Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery" 한국유방암학회 19 (19): 185-190, 2016

6 Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013" 24 : 2206-2223, 2013

7 Bustreo S, "Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation : a large case series study with a long-term follow-up" 157 : 363-371, 2016

8 Williams KE, "Molecular phenotypes of DCIS predict overall and invasive recurrence" 26 : 1019-1025, 2015

9 Keong Won Yun ; Jisun Kim ; Jong Won Lee ; Sae Byul Lee ; Hee Jeong Kim ; Il Young Chung ; Beom Seok Ko ; Byung Ho Son ; Sei Hyun Ahn, "Long-term Follow-up of Pure Ductal Carcinoma in situ after Breast-Conserving Surgery" 한국유방암학회 7 (7): 73-80, 2019

10 Poulakaki N, "Ki-67 expression as a factor predicting recurrence of ductal carcinoma in situ of the breast : a systematic review and meta-analysis" 18 : 157-167. e6, 2018

11 Cocco D, "Invasive lobular breast cancer : data to support surgical decision making" 28 : 5723-5729, 2021

12 Allison KH, "Estrogen and progesterone receptor testing in breast cancer : ASCO/CAP guideline update" 38 : 1346-1366, 2020

13 Cuzick J, "Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ : long-term results from the UK/ANZ DCIS trial" 12 : 21-29, 2011

14 Yoonsun Choi ; TAE SIK HWANG ; Ah-Rem Jeong ; Joung Won Na ; Yun Young Kim ; Joon-Hyop Lee ; Yoo Seung Jung ; Sang Tae Choi ; 강진모 ; Heung Kyu Park ; 전용순, "Clinicopathological markers associated with recurrence in ductal carcinoma in situ of breast by age group" 대한종양외과학회 14 (14): 15-20, 2018

15 정규원 ; 원영주 ; 공현주 ; 이은숙, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016" 대한암학회 51 (51): 417-430, 2019

16 Donker M, "Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ : 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial" 31 : 4054-4059, 2013

17 Lee LA, "Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast" 192 : 416-419, 2006

18 Guerrieri-Gonzaga A, "Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS" 139 : 2127-2134, 2016

19 Koh VCY, "Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast : literature review and single-centre retrospective series" 74 : 970-987, 2019

20 National Cancer Information Center, "Annual report of cancer statistics in Korea in 2018" 20-, 2021

21 Forbes JF, "Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ(IBIS-II DCIS) : a double-blind, randomised controlled trial" 387 : 866-873, 2016

22 Sieuwerts AM, "APOBEC3B gene expression in ductal carcinoma in situ and synchronous invasive breast cancer" 11 : 1062-, 2019